How long should patients take medications for postmenopausal osteoporosis?{lozenge, open}{lozenge, open}Pour citer cet article, utiliser ce titre en anglais et sa référence dans le même volume de Joint Bone Spine.;Quelle est la durée optimale des traitements dans l'ostéoporose postménopausique ?

Revue du Rhumatisme (Edition Francaise)

Volumn 74, Issue 1, 2007, Pages 27-34

  Briot, Karine ^a   Trémollières, Florence ^b   Thomas, Thierry ^c   Roux, Christian ^a  

^a Institut Cochin   (France)

^b Paul Sabatier University   (France)

^c UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Bisphosphonates; Bone mineral density; Postmenopausal osteoporosis; SERM. Vertebral fracture

Indexed keywords

EID: 33846643656     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2006.05.022     Document Type: Short Survey

References (37)

1. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
2. Harris S.T., Watts N.B., and Genant H.K. Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282 (1999) 1344-1352
3. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
4. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifène. Results from a 3-year randomized clinical trial. JAMA 282 (1999) 637-645
5. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350 (2004) 459-468
6. Liberman U.A., Weiss S.R., Bröll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333 (1995) 1437-1443
7. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
8. Tonino R.P., Meunier P.J., Emkey R., Rodriguez-Portales J.A., Menkes C.J., Wasnich R.D., et al. Skeletal benefits of alendronate: a 7-year treatment of postmenopausal women. J. Clin. Endocrinol. Metab. 85 (2000) 3109-3115
9. Bone H.G., Hosking D.H., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350 (2004) 1189-1199
10. Ott S.M. Fractures after long-term Alendronate therapy. JCEM 86 (2001) 1835-1836
11. Lindsay R., Pack S., and Li Z. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteopororsis. Osteoporos. Int. 16 (2005) 306-312
12. Ensrud K.E., Barrett-Connor E.L., Schwartz A., Santora A.C., Bauer D.C., Suryawanshi S., et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the fracture intervention trial long-term extension. J. Bone Miner. Res. 19 (2004) 1259-1269
13. Black D., Schwartz A., Ensrud K., Ryback-Feiglin A., Gupta J., Lombardi A., et al. A 5 year randomized trial of the long-term efficacy and safety of Alendronate: the FIT Long-Term Extension (FLEX). J. Bone Miner. Res. 19 (2004) S45
14. Reginster J.Y., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int. 11 (2000) 83-91
15. Mc Clung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Hip intervention program study group: effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N. Engl. J. Med. 344 (2001) 333-340
16. Sorensen O.H., Crawford G.M., Mulder H., Hosking D.J., Gennari C., Mellsröm D., et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32 (2003) 120-126
17. Mellstrom D., Sorensen O.H., Goemaere S., Roux C., Johnson T.D., and Chines A.A. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif. Tissue Int. 75 (2004) 462-468
18. Mortensen L., Charles P., Bekker P.J., Digennaro J., and Johnston Jr. C.C. Risedronate increases bone mass is early postmenopausal population: two years of treatement plus one year of follow-up. J. Clin. Endocrinol. Metab. 83 (1998) 396-402
19. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzl P., and Klaushofer K. Alendronate increases degree and uniformity of mineralization of cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29 (2001) 185-191
20. Borah B., Dufresne T.E., Chmielewski P.A., Gross G.J., Prenger M.C., and Phipps R.J. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J. Bone Miner. Res. 17 (2002) 1139-1147
21. Otomo H., Sakai A., Ikeda S., Tanaka S., Ito M., Phipps R.J., et al. Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2. J. Bone Miner. Metab. 22 (2004) 404-414
22. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates A.J., and Meunier P.J. Alendronate increases bone strength by increasin the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 (2000) 686-694
23. Dufresne T.E., Chmielewski P.A., Manhart M.D., Johnson T.D., and Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif. Tissue Int. 73 (2003) 423-432
24. Ste-Marie L.G., Sod E., Johnson T., and Chines A. Five years of treatment with risedronate an its effectson bone safety in women with postmenopausal osteoporosis. Calcif. Tissue Int. 75 (2004) 469-476
25. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Jacob D.S., Johnston C.C., et al. Effects of high-dose etidronate treatment on microdamage accumulation and biochemical properties in beagle bone before occurrence of spontaneous fractures. Bone 29 (2001) 271-278
26. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., and Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biochemical properties in clinically relevant skeletal sites in beagles. Bone 28 (2001) 524-531
27. Akkus O., Polyakova-Akkus A., Adar F., and Schaffler M.B. Aging of microstructural compartments in human compact bone. J. Bone Miner. Res. 18 (2003) 1012-1019
28. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., and Pak C.Y.C. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90 (2005) 1294-1301
29. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62 (2004) 527-534
30. Khan S.A., Kanis J.A., Vasikaran S., Kline W.F., Matuszewski B.K., McCloskey E.V., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J. Bone Miner. Res. 12 (1997) 1700-1707
31. Delmas P.D., Ensrud K.E., Adachi J.D., Harper K.D., Sarkar S., Gennari C., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 87 (2002) 3609-3617
32. Martino S., Cauley J.A., Barrett-Connor E., Powles T.J., Mershon J., Disch D., et al. Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst. 96 (2004) 1751-1761
33. Siris E.S., Harris S.T., Eastell R., Zanchetta J.R., Goemaere S., Diez-Perez A., et al. Cummings SR and For the Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of Raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J. Bone Miner. Res. 20 (2005) 1514-1524
34. Neele S.J., Evertz R., De Valk-De Roo G., Roos J.C., and Netelenbos J.C. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30 (2002) 599-603
35. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized study. JAMA 281 (1999) 2189-2197
36. Lindsay R., Scheele W.H., Neer R., Pohl G., Adami G., Mautalen C., et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Intern. Med. 164 (2004) 2024-2030
37. Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90 (2005) 2816-2822